ESCAPE Bio

About:

ESCAPE Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases.

Website: https://www.escapebio.com/

Top Investors: OrbiMed, Wellington Management, Sutter Hill Ventures, Novo Holdings, Surveyor Capital

Description:

Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.